Sign inJoin waitlistJoin the waitlist

GD

Gerald DeNardo

Credentials: · ·

History

Hematology and Medical Oncology
Internal Medicine

Research

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
Cancer Research · 2002 · Last of 6 authors · 190 citations
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
Journal of Clinical Oncology · 1998 · First of 10 authors · Corresponding · 168 citations
Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1
Cancer Research · 1990 · First of 6 authors · 141 citations

SD
Sally DeNardo
212 papers
RO
Robert O'Donnell
48 papers
CR
Carol Richman
20 papers
AE
Alan Epstein
9 papers · 1 as a fellow
Daniel Berman
9 papers · 9 as a fellow
AS
Antone Salel
8 papers
RD
Robert D'Ambrosia
7 papers
Frederick Meyers
6 papers
Kit Lam
5 papers
RW
Richard Wilder
5 papers
Ezra Amsterdam
4 papers
BL
Bryan Leigh
3 papers

Grants

Translational Multimodality " Antibody" Therapy
National Cancer Institute · P01
Contact PI · $24.2M · University of California at Davis
1988–2009
31-p Nmr Prediction of Efficacy of Radioimmunotherapy
National Cancer Institute · R01
Contact PI · $370.2K · University of California at Davis
1986–1990

Clinical trials

Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Study chair · Unknown · Phase 1
University of California, Davis
2001
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Study chair · Unknown · Phase 1
University of California, Davis
2001